We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical and molecular events in patients with Machado–Joseph disease under lamotrigine therapy.
- Authors
Liu, C.-S.; Hsu, H.-M.; Cheng, W.-L.; Hsieh, M.
- Abstract
Liu C-S, Hsu H-M, Cheng W-L, Hsieh M. Clinical and molecular events in patients with Machado–Joseph disease under lamotrigine therapy.Acta Neurol Scand 2005: 111: 385–390.© Blackwell Munksgaard 2005.Machado–Joseph disease (MJD)/spinocerebellar ataxia type 3 is an autosomal dominant spinocerebellar degeneration, for which there is no effective treatment.This study involved the clinical response of lamotrigine (LTG) on six MJD patients with early truncal ataxia and the effect of LTG on the alteration of ataxin-3 expression in the transformed MJD lymphoblastoid cells.LTG medication was found, on the basis of single leg standing test tandem gait index, to effectively improve gait balance, but did not prove to be effective in the withdrawal period. In Western blot analysis of ataxin-3 in MJD lymphoblastoid cells, extracellular application of LTG, while leaving the normal level of ataxin-3 intact, decreased the expression of mutant ataxin-3 in a dose-related manner.Our results indicated that LTG may have significant benefits in relief of gait disturbance in MJD patients with early ataxia, and may be related to the decreased expression of mutant ataxin-3.
- Subjects
PATIENTS; LAMOTRIGINE; ANTICONVULSANTS; TRIAZINES; HUMAN heredity; FRIEDREICH'S ataxia
- Publication
Acta Neurologica Scandinavica, 2005, Vol 111, Issue 6, p385
- ISSN
0001-6314
- Publication type
Article
- DOI
10.1111/j.1600-0404.2005.00405.x